BIOSIMILARS UPDATE: 2019 Report

2019 and 2020 are expected to be pivotal years for biosimilars in the US, with multiple launches during this time frame.3,4 The availability of more biosimilars on the market will result in competition that has the potential to lead to significant savings for the healthcare system10 and these savings can be deployed to newer, innovative treatments. ................
................